Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MIST Stock Forecast 2026-2027
$1.27
Current Price
$161.85M
Market Cap
Buy 5
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to MIST Price Targets
+529.9%
To High Target of $8.00
+451.2%
To Median Target of $7.00
+57.5%
To Low Target of $2.00
MIST Price Momentum
-3.1%
1 Week Change
-1.6%
1 Month Change
-24.0%
1 Year Change
-37.1%
Year-to-Date Change
-58.5%
From 52W High of $3.06
+27.0%
From 52W Low of $1.00
📊 TOP ANALYST CALLS
Did MIST Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Milestone is one of their latest high-conviction picks.
Latest MIST Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, MIST has a bullish consensus with a median price target of $7.00 (ranging from $2.00 to $8.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $1.27, the median forecast implies a 451.2% upside. This outlook is supported by 5 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MIST Analyst Ratings
5
Buy
1
Hold
0
Sell
MIST Price Target Range
Low
$2.00
Average
$7.00
High
$8.00
Current: $1.27
Latest MIST Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MIST.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 14, 2026 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $7.00 |
| Jan 6, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 16, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Dec 15, 2025 | TD Cowen | Buy | Upgrade | $N/A | |
| Dec 15, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Sep 11, 2025 | Wells Fargo | Overweight | Initiates | $N/A | |
| Jun 5, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Assumes | $5.00 |
| Apr 1, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 28, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 17, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 28, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 27, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 14, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 22, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 22, 2024 | Rodman & Renshaw | Buy | Initiates | $N/A | |
| Jul 1, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 30, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 16, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 22, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 5, 2024 | Piper Sandler | Overweight | Maintains | $N/A |
Milestone Pharmaceuticals Inc. (MIST) Competitors
The following stocks are similar to Milestone based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MIST
Milestone Pharma
mkt cap
159.36M
Milestone Pharmaceuticals Inc. (MIST) Financial Data
Milestone Pharmaceuticals Inc. has a market capitalization of $161.85M with a P/E ratio of -1.7x. The company generates $1.78M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -84.6% quarter-over-quarter, while maintaining an operating margin of -9,942.4% and return on equity of -456.9%.
Valuation Metrics
Market Cap
$161.85M
Enterprise Value
$124.90M
P/E Ratio
-1.7x
PEG Ratio
0.0x
Price/Sales
90.0x
Growth & Margins
Revenue Growth (YoY)
-84.6%
Gross Margin
+94.1%
Operating Margin
-9,942.4%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+108.1%
Current Ratio
9.2x
Debt/Equity
380.9x
ROE
-456.9%
ROA
-31.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Milestone Pharmaceuticals Inc. (MIST) Business Model
About Milestone Pharmaceuticals Inc.
What They Do
Develops treatments for cardiovascular conditions.
Business Model
Milestone Pharmaceuticals focuses on developing and commercializing innovative therapies for episodic cardiovascular conditions, generating revenue primarily through the sale of its FDA-approved product, etripamil. The company emphasizes a lean operational model, investing significantly in research and development to drive clinical trials and future product offerings.
Additional Information
Founded in 2003 and headquartered in Montreal, Canada, Milestone has a seasoned leadership team with expertise in cardiovascular medicine and drug development. The company is also exploring etripamil's potential applications for other cardiovascular conditions, which may present additional market opportunities.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
38
CEO
Mr. Joseph G. Oliveto M.B.A.
Country
Canada
IPO Year
N/A
Website
www.milestonepharma.comMilestone Pharmaceuticals Inc. (MIST) Latest News & Analysis
Latest News
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 days ago
Quick Summary
Milestone Pharmaceuticals Inc. granted 288,000 options to purchase common shares to attract six new employees, under its 2021 Inducement Plan, approved by its Compensation Committee.
Why It Matters
Milestone Pharmaceuticals' equity awards signal growth and potential expansion, which could enhance investor confidence and affect stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Milestone Pharmaceuticals Inc. (MIST) Shareholder/Analyst Call Prepared Remarks Transcript
1 month ago
Quick Summary
Milestone Pharmaceuticals Inc. (MIST) held a shareholder/analyst call, where they discussed company updates and financial performance. Further details can be found in the transcript.
Why It Matters
The transcript reveals insights into Milestone Pharmaceuticals' performance, strategies, and future outlook, influencing investor sentiment and stock price movements.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Milestone Pharmaceuticals Inc. is rated a Strong Buy despite a 37% stock drop post-FDA approval of Cardamyst. Key factors include Cardamyst's efficacy, insurance coverage, and potential for market expansion.
Why It Matters
Milestone Pharmaceuticals' strong buy rating amid stock decline signals potential recovery. Cardamyst's efficacy and expansion plans may drive future revenue and market growth.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) announced its first-quarter earnings on Wednesday before market open. Further details were not provided in the excerpt.
Why It Matters
Milestone Pharmaceuticals' earnings report may influence stock performance, affecting investor sentiment and potential market volatility based on financial results and future projections.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Milestone Pharmaceuticals (NASDAQ: MIST) announced commercial sales of CARDEMYST, a treatment for PSVT, began in Q1 2026, and they are advancing a Phase 3 program for atrial fibrillation.
Why It Matters
Milestone Pharmaceuticals' first commercial sales of CARDEMYST and ongoing Phase 3 trials indicate potential revenue growth and market expansion, positively impacting investor sentiment and stock performance.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
Milestone Pharmaceuticals Inc. (MIST) reported its Q1 2026 earnings, providing insights into financial performance and corporate developments. Full details are available in their earnings call transcript.
Why It Matters
Milestone Pharmaceuticals' Q1 2026 earnings call reveals key financial metrics and strategic developments, impacting stock performance and investor sentiment regarding future growth.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About MIST Stock
What is Milestone Pharmaceuticals Inc.'s (MIST) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Milestone Pharmaceuticals Inc. (MIST) has a median price target of $7.00. The highest price target is $8.00 and the lowest is $2.00.
Is MIST stock a good investment in 2027?
According to current analyst ratings, MIST has 5 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.27. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MIST stock?
Wall Street analysts predict MIST stock could reach $7.00 in the next 12 months. This represents a 451.2% increase from the current price of $1.27. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Milestone Pharmaceuticals Inc.'s business model?
Milestone Pharmaceuticals focuses on developing and commercializing innovative therapies for episodic cardiovascular conditions, generating revenue primarily through the sale of its FDA-approved product, etripamil. The company emphasizes a lean operational model, investing significantly in research and development to drive clinical trials and future product offerings.
What is the highest forecasted price for MIST Milestone Pharmaceuticals Inc.?
The highest price target for MIST is $8.00 from at , which represents a 529.9% increase from the current price of $1.27.
What is the lowest forecasted price for MIST Milestone Pharmaceuticals Inc.?
The lowest price target for MIST is $2.00 from at , which represents a 57.5% increase from the current price of $1.27.
What is the overall MIST consensus from analysts for Milestone Pharmaceuticals Inc.?
The overall analyst consensus for MIST is bullish. Out of 3 Wall Street analysts, 5 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are MIST stock price projections?
Stock price projections, including those for Milestone Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 2:46 AM UTC